Dimensional Fund Advisors LP increased its holdings in Ignyta, Inc. (NASDAQ:RXDX) by 6.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 61,114 shares of the biopharmaceutical company’s stock after purchasing an additional 3,946 shares during the quarter. Dimensional Fund Advisors LP owned 0.15% of Ignyta worth $526,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. American International Group Inc. raised its holdings in shares of Ignyta by 7.1% in the 1st quarter. American International Group Inc. now owns 18,148 shares of the biopharmaceutical company’s stock worth $156,000 after purchasing an additional 1,197 shares in the last quarter. Wells Fargo & Company MN raised its holdings in shares of Ignyta by 4.8% during the first quarter. Wells Fargo & Company MN now owns 21,885 shares of the biopharmaceutical company’s stock valued at $188,000 after acquiring an additional 1,000 shares during the period. Trexquant Investment LP purchased a new position in Ignyta during the first quarter valued at approximately $219,000. TFS Capital LLC grew its position in Ignyta by 5.5% during the first quarter. TFS Capital LLC now owns 32,486 shares of the biopharmaceutical company’s stock valued at $279,000 after purchasing an additional 1,680 shares in the last quarter. Finally, Neuberger Berman Group LLC purchased a new position in Ignyta during the first quarter valued at approximately $366,000. Institutional investors and hedge funds own 80.82% of the company’s stock.
Shares of Ignyta, Inc. (NASDAQ RXDX) traded up 0.661% during midday trading on Friday, reaching $11.425. 690,818 shares of the company’s stock were exchanged. The stock’s market cap is $642.69 million. The company’s 50 day moving average is $9.97 and its 200-day moving average is $8.90. Ignyta, Inc. has a 12 month low of $4.15 and a 12 month high of $12.45.
Ignyta (NASDAQ:RXDX) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.63) by $0.07. Equities analysts forecast that Ignyta, Inc. will post ($2.57) EPS for the current fiscal year.
A number of research analysts recently commented on RXDX shares. Zacks Investment Research downgraded shares of Ignyta from a “hold” rating to a “sell” rating in a research report on Wednesday, May 24th. Cantor Fitzgerald set a $15.00 price objective on shares of Ignyta and gave the stock a “buy” rating in a research note on Sunday, June 4th. Jefferies Group LLC restated a “buy” rating and issued a $27.00 price objective on shares of Ignyta in a research note on Thursday, June 22nd. ValuEngine upgraded shares of Ignyta from a “sell” rating to a “hold” rating in a research note on Thursday, June 15th. Finally, BidaskClub cut shares of Ignyta from a “buy” rating to a “hold” rating in a research note on Friday, July 28th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $17.33.
Ignyta, Inc is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company’s pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106.
Receive News & Ratings for Ignyta Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ignyta Inc. and related companies with our FREE daily email newsletter.